Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22891945 | 1.00 | DGAT1 (0.34) | DGAT1KDM4EPKMCA1CA2 | |
| SCHEMBL22891947 | 0.84 | TSHR (0.33) | — | |
| SCHEMBL28344784 | 0.83 | DGAT1 (0.34) | DGAT1CA1CA2CA7MMP8 | |
| SCHEMBL25761623 | 0.78 | NAALAD2 (0.36) | — | |
| SCHEMBL20980751 | 0.78 | NAALAD2 (0.36) | — | |
| SCHEMBL19764845 | 0.78 | NAALAD2 (0.36) | — | |
| SCHEMBL12885564 | 0.77 | KISS1R (0.32) | DGAT1 | |
| SCHEMBL16417529 | 0.76 | ACACB (0.33) | PKMCA1CA2 | |
| SCHEMBL10257080 | 0.76 | ACACB (0.33) | PKMCA1CA2 | |
| SCHEMBL10257384 | 0.76 | ACACB (0.33) | PKMCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872217-B2 | Indanes as PD-L1 inhibitors | CHEMOCENTRYX, INC. (US) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872217-B2 | Indanes as PD-L1 inhibitors | CD274, PDCD1, PDCD1LG2 | DGAT1 4697/4885KDM4E 953/4885PKM 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.